CALC CalciMedica, Inc.
Company Analysis
Latest News
CalciMedica Announces 1-for-5 Reverse Stock Split and Reduction of Authorized Shares
CalciMedica, Inc. filed a Certificate of Amendment to enact a 1-for-5 reverse stock split of its common stock, effective at 5:00 p.m. ET on August 28, 2026....
CalciMedica's Reverse Stock Split Buys Time on Nasdaq, but Can a Sub-Dollar Biotech Survive the Signal It Sends?
Shares of CalciMedica (CALC) tumbled 14.9% to $0.50 on August 27, 2026, after the clinical-stage biotech announced a one-for-five reverse stock split — a move...
🔴 CalciMedica is trading 14.89% down today after announcing a reverse split to restore Nasdaq compliance
CalciMedica is trading at $0.50 (-14.89%) after announcing a one-for-five reverse stock split intended to restore compliance with Nasdaq’s minimum bid-price...
🔴 CalciMedica is trading 9.74% down today as immediate catalyst remains unclear
CalciMedica is trading 9.74% down now at $0.53 after no verified company-specific announcement dated August 26 or August 27 was identified. - The latest...
🔴 CalciMedica is trading 9.79% down in pre-market; no verified company-specific catalyst identified
CalciMedica is trading 9.79% down at $0.53, with no verified company-specific catalyst identified. - It closed at $0.59 on August 26, 2026; no verified...
🟢 CalciMedica is trading 5.53% up in after-hours trading with no verified new company announcement
CalciMedica is trading 5.53% up in after-hours trading at $0.62 after closing at $0.59 on August 26, 2026, with no verified new company-specific catalyst. -...
🟢 CalciMedica, Inc. is trading 5.03% up
CALC is trading at $0.58, up 5.03%.
🟢 CalciMedica is trading 5% up in pre-market after Guggenheim's Buy rating and $9.00 target
CalciMedica is trading 5.12% up in pre-market at $0.60 after Guggenheim initiated coverage with a Buy rating and a $9.00 price target on August 20, 2026. -...
🟢 CalciMedica is trading 6.65% up in after-hours trading after Guggenheim's Buy initiation
CalciMedica is trading 6.65% up at $0.62 after Guggenheim initiated coverage on August 20, 2026, with a Buy rating and a $9.00 price target. - The positive...
🔴 CalciMedica is trading 5.6% down today after reverse split approval
CalciMedica is trading 5.6% down at $0.58 after shareholders approved a reverse stock split ranging from 1-for-2 to 1-for-10 and expanded the company’s equity...
CalciMedica Stockholders Approve Reverse Stock Split and Incentive Plan Expansion
CalciMedica, Inc. announced that stockholders approved several key proposals at its 2026 Annual Meeting of Stockholders held on August 19, 2026. The approved...
🟢 CalciMedica is trading 11.17% up in pre-market as XBI rises 2.27%
CalciMedica is trading at $0.68, up 11.17% in pre-market, primarily on biotech-sector strength. - No new CalciMedica company-specific announcement was...
🟢 CalciMedica is trading 6% up in pre-market as biotech ETF XBI gains 2.27%
CalciMedica is trading at $0.65, up +6.02%, as a 2.27% pre-market gain in biotech ETF XBI points to sector-wide risk appetite. - No new company-specific...
🔴 CalciMedica is trading 5.58% down today
CalciMedica is trading 5.58% down at $0.61, with no clearly reported company-specific announcement explaining the August 19, 2026 move. - The company’s annual...
🟢 CalciMedica is trading 5% up in after-hours trading; no new company-specific announcement directly explaining the move
CalciMedica is trading 5.17% up now at $0.71 after closing at $0.68 on August 14, 2026; no new company-specific announcement directly explaining the...
CalciMedica Rallies 11% on FDA Nod and Cash Lifeline, but Can a Sub-Dollar Stock Deliver on Its Pancreatitis Bet?
Shares of CalciMedica surged to $0.69, up 11% from the prior close, as investors digested a pair of catalysts: the FDA's agreement on a clearer path for the...
🟢 CalciMedica is trading 11% up today as FDA aligns on Auxora trial endpoint
CalciMedica is trading 11% up at $0.69 as investors focus on FDA alignment for Auxora’s Phase 2b acute-pancreatitis trial despite a wider-than-expected...
🟢 CalciMedica is trading 8.08% up today after July PPI showed no monthly growth
CalciMedica is trading at $0.67, up +8.08%, as U.S. markets rally after July PPI showed no monthly growth, below the expected 0.2% increase. - The S&P 500,...
CalciMedica misses second quarter 2026 EPS estimates as FDA aligns on pancreatitis trial design
CalciMedica reported a second quarter 2026 net loss of $0.45 per share, missing consensus estimates by $0.12. Despite the wider loss, the company achieved a...
🟢 CalciMedica is trading 5% up in pre-market
CalciMedica is trading 5.16% up at $0.69 after closing at $0.66 on August 10, 2026, with no new company-specific announcement or clear overnight catalyst...